Twist Bioscience Soared — We're Still Not Buying

Twist Bioscience (TWST) just had a massive run-up after Anthropic's protein design results put its DNA synthesis platform in the spotlight. Here's what's really driving the stock — and whether it's still a buy. Twist Bioscience (NASDAQ: TWST) has surged in recent months, fueled by growing demand for AI-enabled drug discovery and a high-profile 8-K disclosure tied to Anthropic's protein design campaign. In this deep dive, CSI breaks down Twist's silicon-based DNA synthesis platform, how it differs from traditional synthesis methods, and why manufacturing costs have fallen sharply over the past three years. We cover the two core segments — DNA synthesis and protein solutions versus next-gen sequencing (NGS) — and which one is growing faster. We also unpack customer trends across therapeutics, diagnostics, academic/government, and industrial markets, plus the strategic rationale behind spinning off the Atlas Data Storage business. From there, we walk through Twist's fiscal 2026 guidance, free cash flow trajectory, and the dilution risk created by its $200 million and $300 million at-the-market equity offerings. Finally, we run two reverse discounted cash flow (DCF) scenarios to stress-test what the market may be pricing in today, and explain why the current semiconductor-adjacent biotech valuation still looks rich despite the growth story. Is TWST a buy after this run, or still just a watch-list name? 👉Visit https://fiscal.ai/csi for 15% off any paid plan! If you want the reasoning behind more names like this one, Semiconductor Insider covers the process in more depth. Get access to all our research, weekly live Q&A events, and a growing set of tools to build your process: https://www.chipstockinvestor.com 📰 Why Chip Stock Investor Is Becoming a Software Business: https://chipstockinvestor.com/why-chip-stock-investor-is-becoming-a-software-business/ Linktree for all our socials: https://linktr.ee/chipstockinvestor If you found this video useful, please make sure